SecSonar.com

Ginkgo Bioworks Holdings, Inc. (DNA)

Ginkgo Bioworks Holdings, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Ginkgo Bioworks Holdings, Inc. (DNA) is a Biotechnology company based in US with a market capitalization of $628.4M. Revenue declined 25.1% year-over-year and free cash flow was negative at -$178.7M. This page tracks DNA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 834 employees · IPO Apr 19, 2021

Valuation

Valuation & price

$7.71 · as of May 17, 2026 · -52.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.24

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$16.14$11.04$5.93Jul 25Dec 25Jun 26Jul 7, 25$11.35Jul 9, 25$11.07Jul 11, 25$9.98Jul 15, 25$9.43Jul 17, 25$9.76Jul 21, 25$11.32Jul 23, 25$14.14Jul 25, 25$13.96Jul 29, 25$12.92Jul 31, 25$13.14Aug 4, 25$13.60Aug 6, 25$13.96Aug 8, 25$12.29Aug 12, 25$11.56Aug 14, 25$12.90Aug 18, 25$13.80Aug 20, 25$11.59Aug 22, 25$12.55Aug 27, 25$12.35Aug 29, 25$12.67Sep 3, 25$11.33Sep 5, 25$11.15Sep 9, 25$10.76Sep 11, 25$10.44Sep 15, 25$10.27Sep 17, 25$11.07Sep 19, 25$11.37Sep 23, 25$12.35Sep 25, 25$11.25Sep 29, 25$13.23Oct 1, 25$14.67Oct 3, 25$16.14Oct 7, 25$14.82Oct 9, 25$15.24Oct 13, 25$13.16Oct 16, 25$15.12Oct 20, 25$13.63Oct 22, 25$12.78Oct 24, 25$13.57Oct 28, 25$12.74Oct 30, 25$12.01Nov 3, 25$12.79Nov 5, 25$11.59Nov 7, 25$8.95Nov 11, 25$8.46Nov 13, 25$8.00Nov 17, 25$7.78Nov 19, 25$7.91Nov 21, 25$8.17Nov 25, 25$8.71Nov 28, 25$9.28Dec 2, 25$8.59Dec 5, 25$9.25Dec 9, 25$9.56Dec 11, 25$9.90Dec 15, 25$8.67Dec 17, 25$8.24Dec 19, 25$8.10Dec 23, 25$8.77Dec 26, 25$8.40Dec 30, 25$8.15Jan 2, 26$8.70Jan 6, 26$9.17Jan 8, 26$9.06Jan 12, 26$9.56Jan 14, 26$9.85Jan 16, 26$9.55Jan 21, 26$9.78Jan 23, 26$10.02Jan 28, 26$9.43Jan 30, 26$8.97Feb 3, 26$8.79Feb 5, 26$8.32Feb 9, 26$10.15Feb 11, 26$9.35Feb 13, 26$9.29Feb 18, 26$8.95Feb 20, 26$9.22Feb 24, 26$8.86Feb 26, 26$9.71Mar 2, 26$7.05Mar 4, 26$6.69Mar 6, 26$6.50Mar 10, 26$6.34Mar 12, 26$6.40Mar 16, 26$6.75Mar 19, 26$6.91Mar 23, 26$6.99Mar 25, 26$7.36Mar 27, 26$5.93Mar 31, 26$6.13Apr 2, 26$6.90Apr 7, 26$6.82Apr 9, 26$6.43Apr 13, 26$6.68Apr 15, 26$7.79Apr 17, 26$8.03Apr 21, 26$8.21Apr 23, 26$7.70Apr 27, 26$7.82Apr 29, 26$7.50May 1, 26$9.70May 5, 26$9.71May 8, 26$8.93May 12, 26$8.34May 14, 26$7.85May 18, 26$7.37May 20, 26$7.72May 22, 26$8.41May 27, 26$8.71May 29, 26$9.37Jun 2, 26$9.33Jun 4, 26$9.05Jun 8, 26$8.09Jun 10, 26$7.94Jun 12, 26$7.89Jun 16, 26$8.21Jun 18, 26$9.17Jun 23, 26$8.86Jun 29, 26$10.44
$5.4852-week range$16.14
Loading valuation history…

Fundamentals

Key fundamentals

$628.4M

Market cap

-25.1%

Revenue growth (YoY)

81.5%

Gross margin

-$178.7M

Free cash flow (USD)

-$5.5M

Net debt

Net cash position

6.9%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$54.2MFY 2020$76.7MFY 2021$313.8MFY 2022$477.7MFY 2023$251.5MFY 2024$227.0MFY 2025$170.2M
$54.2M$170.2M

Free cash flow by year

2019 → 2025

FY 2019$-66.9MFY 2020$-193.7MFY 2021$-310.3MFY 2022$-304.5MFY 2023$-336.3MFY 2024$-382.1MFY 2025$-178.7M
-$66.9M-$178.7M

Gross margin by year

2021 → 2025

FY 202158.7%FY 202257.3%FY 202378.5%FY 202483.0%FY 202581.5%
58.7%81.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

8

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 12, 2026Filing
  • Insider sellInsider Sell $3KCoen Steven P. · See remarks · $2.6KMay 26, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • Insider sellInsider Sell $3KCoen Steven P. · See remarks · $2.6KApr 20, 2026Filing
  • Insider sellInsider Sell $213KCoen Steven P. · See remarks · $212.8KApr 14, 2026Filing
  • Insider sellInsider Sell $802KShetty Reshma P. · Director, See remarks, 10% Owner · $802.5KApr 13, 2026Filing
  • Insider sellInsider Sell $802KCanton Barry · 10% Owner · $802.5KApr 13, 2026Filing
  • Insider sellInsider Sell $1.4MKelly Jason R · Director, See remarks · $1.4MApr 10, 2026Filing
  • Insider sellInsider Sell $175KCanton Barry · 10% Owner · $175.1KApr 10, 2026Filing

Questions

Frequently asked questions

What is Ginkgo Bioworks Holdings, Inc.'s market cap?

Ginkgo Bioworks Holdings, Inc. (DNA) has a market capitalization of $628.4M.

What is DNA's P/E ratio?

A meaningful P/E ratio is not available for DNA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is DNA's price-to-book (P/B) ratio?

DNA trades at 1.24 times book value per share.

Are insiders buying DNA stock?

SEC Form 4 filings show no open-market insider buys at Ginkgo Bioworks Holdings, Inc. in the last 90 days (8 sells).

Same arena

Related companies in Biotechnology

PRME

Prime Medicine, Inc.

$632.2M

PROK

ProKidney Corp.

$621.5M

BIOA

BioAge Labs, Inc.

$646.1M

ESPR

Esperion Therapeutics, Inc.

$650.8M

ANL

Adlai Nortye Ltd.

$652.4M

CBIO

Crescent Biopharma, Inc.

$598.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.